Risk of Hospitalized COVID ‐19 in COPD : Single‐Inhaler Triple Versus Dual Bronchodilator Therapy
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70321 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Simon Galmiche und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Epidemiology, Lady Davis Institute (LDI), Jewish General Hospital, Montreal, Canada. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Hospitalization, COVID-19, Bronchodilator Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), Canadian Foundation for Innovation (CFI).
Themen: COPD
Abstract (Originalsprache)
Purpose
Our objective was to estimate the effect of initiating an inhaled corticosteroids‐containing single‐inhaler triple agent (ICS‐LABA‐LAMA) compared with a single‐inhaler LABA‐LAMA dual bronchodilator in patients with COPD on the risk of severe COVID‐19 prior to the roll‐out of vaccines.
Methods
We conducted a cohort study emulating a randomized trial, among patients with COPD aged 40 years or more in the UK, comparing those who initiated a triple inhaler with those who initiated a dual bronchodilator inhaler between March 1 and December 31, 2020. Weighting by fine stratification of the propensity score was used to account for confounders. The risk of hospitalized COVID‐19 was compared with a Cox proportional hazards model in an as‐treated analysis with a 30‐day grace period.
Results
The study cohort included 876 patients initiating a triple inhaler and 5010 initiating a dual LABA‐LAMA inhaler. The adjusted incidence rate of hospitalized COVID‐19 was 5.6 per 100 person‐years in the triple inhaler group and 2.9 per 100 person‐years in the dual inhaler group, with a corresponding hazard ratio (HR) of 1.96 (95% confidence interval 1.01–3.77). Sensitivity analyses on the duration of the grace period, using an intent‐to‐treat exposure classification, or starting follow‐up 14 days after treatment initiation (accounting for treatment initiation for an undocumented SARS‐CoV‐2 infection) were generally consistent with the main analysis.
Conclusions
Patients with COPD prescribed an ICS‐containing triple inhaler were potentially exposed to an increased risk of severe COVID‐19 prior to the vaccine era. As SARS‐CoV‐2 continues to cause significant burden, these findings should be considered when determining initiation of inhaled treatment in COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Epidemiology, Lady Davis Institute (LDI), Jewish General Hospital, Montreal, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
ORCID-Profile: Samy Suissa
Förderung
- Canadian Institutes of Health Research (CIHR)
- Canadian Foundation for Innovation (CFI)
Zitieren
APA
Galmiche, S., Dell'Aniello, S., & Suissa, S. (2026). Risk of Hospitalized COVID ‐19 in COPD : Single‐Inhaler Triple Versus Dual Bronchodilator Therapy. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70321
Vancouver
Galmiche S, Dell'Aniello S, Suissa S. Risk of Hospitalized COVID ‐19 in COPD : Single‐Inhaler Triple Versus Dual Bronchodilator Therapy. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70321
BibTeX
@article{Galmiche2026,
author = {Galmiche, Simon and Dell'Aniello, Sophie and Suissa, Samy},
title = {Risk of Hospitalized COVID ‐19 in COPD : Single‐Inhaler Triple Versus Dual Bronchodilator Therapy},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70321}
}
EUVIMED